Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 6
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean simone celani (36 results)?
Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
Rosano GMC, Celant S, Olimpieri PP, Colatrella A, Onder G, Di Lenarda A, Ambrosio G, Reboldi G, Gensini GF, Colivicchi F, Russo P. Rosano GMC, et al. Among authors: celant s. Eur J Heart Fail. 2022 May;24(5):855-860. doi: 10.1002/ejhf.2490. Epub 2022 Mar 31. Eur J Heart Fail. 2022. PMID: 35303393 Free PMC article.
Under-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period.
Onder G, Olimpieri PP, Celant S, Di Lenarda A, Ambrosio G, Reboldi G, Gensini G, Colatrella A, Palmer K, Gabrielli D, Russo P; AIFA Monitoring Registries Group. Onder G, et al. Among authors: celant s. Eur J Prev Cardiol. 2022 Mar 30;29(4):e149-e152. doi: 10.1093/eurjpc/zwab096. Eur J Prev Cardiol. 2022. PMID: 34151366 Free PMC article. No abstract available.
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
Breccia M, Olimpieri PP, Celant S, Olimpieri OM, Pane F, Iurlo A, Summa V, Corradini P, Russo P. Breccia M, et al. Among authors: celant s. Ann Hematol. 2023 May;102(5):1257-1259. doi: 10.1007/s00277-023-05168-8. Epub 2023 Mar 13. Ann Hematol. 2023. PMID: 36914888 No abstract available.
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.
Rigolin GM, Olimpieri PP, Summa V, Celant S, Scarfò L, Tognolo L, Ballardini MP, Urso A, Sessa M, Gambara S, Cura F, Fortini M, Ghia P, Cuneo A, Russo P. Rigolin GM, et al. Among authors: celant s. Blood Cancer J. 2023 Jun 28;13(1):99. doi: 10.1038/s41408-023-00865-z. Blood Cancer J. 2023. PMID: 37380630 Free PMC article.
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
Breccia M, Celant S, Olimpieri PP, Olimpieri OM, Pane F, Iurlo A, Cirilli A, Colatrella A, Gozzo L, Pugliese S, Summa V, Foggi P, Corradini P, Russo P; AIFA Monitoring Registries Group. Breccia M, et al. Among authors: celant s. Ann Hematol. 2021 Feb;100(2):481-485. doi: 10.1007/s00277-021-04406-1. Epub 2021 Jan 7. Ann Hematol. 2021. PMID: 33415425
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
Torti C, Olimpieri PP, Bonfanti P, Tascini C, Celant S, Tacconi D, Nicastri E, Tacconelli E, Cacopardo B, Perrella A, Buccoliero GB, Parruti G, Bassetti M, Biagetti C, Giacometti A, Erne EM, Frontuto M, Lanzafame M, Summa V, Spagnoli A, Vestri A, Di Perri G, Russo P, Palù G. Torti C, et al. Among authors: celant s. Lancet Reg Health Eur. 2023 Jul 14;31:100684. doi: 10.1016/j.lanepe.2023.100684. eCollection 2023 Aug. Lancet Reg Health Eur. 2023. PMID: 37547273 Free PMC article.